Foda, Asmaa http://orcid.org/0000-0003-1694-1983
Kellner, Elias
Gunawardana, Asanka
Gao, Xiang
Janz, Martin
Kufner, Anna
Khalil, Ahmed A.
Geran, Rohat
Mekle, Ralf
Fiebach, Jochen B.
Galinovic, Ivana
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
Article History
Received: 10 June 2021
Accepted: 3 December 2021
First Online: 23 December 2021
Declarations
:
: Financial interests: J.B. Fiebach reports consulting and advisory board fees from Abbvie, AC Immune, Artemida, BioClinica, Biogen, BMS, Brainomix, Cerevast, Daiichi-Sankyo, EISAI, F. Hoffmann-La Roche AG, Eli Lilly, Guerbet, Ionis Pharmaceuticals, IQVIA, Janssen, Julius Clinical, jung diagnostics, Lysogene, Merck, Nicolab, Premier Research, and Tau Rx, outside the submitted work. E. Kellner is a shareholder of and receives fees from VEObrain GmbH, Freiburg, Germany. Non-financial interests: none. A. Foda, A. Gunawardana, X. Gao, M. Janz, A. Kufner, A.A. Khalil, R. Geran, R. Mekle, and I. Galinovic declare that they have no competing interests.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the institutional review board of Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin (#EA4/131/19). <i>Consent to participate:</i> written informed consent was obtained from all individual participants (or their legal guardians) included in the study. <i>Consent for publication:</i> not applicable.